Price T Rowe Associates Inc Argenx Se Transaction History

Price T Rowe Associates Inc

$812 Billion
Q1 2025

A detailed history of Price T Rowe Associates Inc transactions in Argenx Se stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,384,586 shares of ARGX stock, worth $3.11 Billion. This represents 0.39% of its overall portfolio holdings.

Number of Shares

5,384,586

Previous 5,516,894 2.4%

Holding current value

$3.11 Billion

Previous $3.39 Billion 6.07%

% of portfolio

0.39%

Previous 0.39%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$571.0 - $671.75 $75.5 Million - $88.9 Million	-132,308 Reduced 2.4%	5,384,586 $3.19 Billion
Q4 2024 Feb 14, 2025	SELL	$520.52 - $638.33 $158 Million - $194 Million	-303,653 Reduced 5.22%	5,516,894 $3.39 Billion
Q3 2024 Nov 14, 2024	BUY	$434.22 - $551.9 $96.4 Million - $123 Million	221,984 Added 3.97%	5,820,547 $3.16 Billion
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $33.5 Million - $42.5 Million	94,057 Added 1.71%	5,598,563 $2.41 Billion
Q1 2024 May 15, 2024	BUY	$356.95 - $413.29 $653 Million - $757 Million	1,830,651 Added 49.83%	5,504,506 $2.17 Billion
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $4.86 Million - $7.26 Million	14,340 Added 0.39%	3,673,855 $1.4 Billion
Q3 2023 Nov 14, 2023	SELL	$369.35 - $548.43 $87.9 Million - $130 Million	-237,904 Reduced 6.1%	3,659,515 $1.8 Billion
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $26.4 Million - $31 Million	73,436 Added 1.92%	3,897,419 $1.52 Billion
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $45.4 Million - $54.8 Million	-135,703 Reduced 3.43%	3,823,983 $1.42 Billion
Q4 2022 Feb 14, 2023	SELL	$342.17 - $402.31 $95.5 Million - $112 Million	-279,003 Reduced 6.58%	3,959,686 $1.5 Billion
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $734 Million - $846 Million	-2,138,627 Reduced 33.53%	4,238,689 $1.5 Billion
Q2 2022 Aug 15, 2022	BUY	$269.58 - $378.88 $49.3 Million - $69.3 Million	182,835 Added 2.95%	6,377,316 $2.42 Billion
Q1 2022 May 16, 2022	BUY	$254.45 - $351.06 $150 Million - $207 Million	590,925 Added 10.55%	6,194,481 $1.95 Billion
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $9.88 Million - $12.8 Million	36,318 Added 0.65%	5,603,556 $1.96 Billion
Q3 2021 Nov 15, 2021	SELL	$295.0 - $350.58 $5.7 Million - $6.77 Million	-19,311 Reduced 0.35%	5,567,238 $1.68 Billion
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $53.2 Million - $66.2 Million	-206,939 Reduced 3.57%	5,586,549 $1.68 Billion
Q1 2021 May 17, 2021	BUY	$268.3 - $380.31 $234 Million - $331 Million	871,508 Added 17.71%	5,793,488 $1.6 Billion
Q4 2020 Feb 16, 2021	BUY	$248.13 - $308.36 $1.22 Billion - $1.52 Billion	4,921,980 New	4,921,980 $1.45 Billion

Others Institutions Holding ARGX

# of Institutions

497

Shares Held

28.5M

Call Options Held

330K

Put Options Held

286K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $32B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Argenx Se Transaction History